3 reports

The estimated cost of the Phase II trial is under $## million.

  • Biopharmaceutical
  • Influenza Antiviral
  • Pharmaceutical
  • United States
  • Can-Fite BioPharma Ltd.

Trial Results Worsening diarrhea Dysuria Headache Dizziness Drowsiness - ## ## ## ## ## - - ## ## Statistical Method (if any) The trial was completed.

  • Gastrointestinal Drug
  • Influenza Antiviral
  • World
  • Product Initiative
  • Glenmark Pharmaceuticals Ltd.

The gastrointestinal AEs previously observed in the ## mg arm were not seen at the ## mg dose.

  • Influenza Antiviral
  • Pharmaceutical
  • United States
  • M&A
  • BioCryst Pharmaceuticals, Inc.